Skip to Main content Skip to Navigation
Journal articles

Exon edited dystrophin rods in the hinge 3 region.

Neha Sahni 1 Khushdeep Mangat 1 Elisabeth Le Rumeur 2 Nick Menhart 1, * 
* Corresponding author
2 Structures et interactions moléculaires
ICM - Interactions cellulaires et moléculaires
Abstract : We have studied the properties of a panel of proteins engineered to be end-products of envisioned exon skipping therapy by antisense oligonucleotides, AONs, directed at exon 51 applied to relevant dystrophin defects causing Duchenne muscular dystrophy, DMD. Exon skipping therapy is a leading therapeutic strategy being investigated for the treatment of this devastating genetic disease. AONs targeting exon 51 have progressed furthest in human clinical trials. Exon 51 skipping is applicable to a variety of dystrophin defects found in different patients. Due to the differences in original defect, the end result of the therapy will be different in each case. An open question is whether these differences will produce significant differences in the dystrophin protein so edited. In this study we have identified differences in the stability, structure and lipid binding properties of these end-product proteins produced by exon 51 skipping repair.
Complete list of metadata
Contributor : Hervé De Villemeur Connect in order to contact the contributor
Submitted on : Thursday, July 12, 2012 - 6:16:40 PM
Last modification on : Wednesday, March 30, 2022 - 2:34:58 PM



Neha Sahni, Khushdeep Mangat, Elisabeth Le Rumeur, Nick Menhart. Exon edited dystrophin rods in the hinge 3 region.. BBA - Biochimica et Biophysica Acta, Elsevier, 2012, 1824 (10), pp.1080-1089. ⟨10.1016/j.bbapap.2012.06.011⟩. ⟨inserm-00717445⟩



Record views